5,875 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Purchased by SG Americas Securities LLC

SG Americas Securities LLC bought a new position in AnaptysBio, Inc. (NASDAQ:ANAB) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,875 shares of the biotechnology company’s stock, valued at approximately $126,000.

Other large investors also recently modified their holdings of the company. Quantbot Technologies LP bought a new stake in shares of AnaptysBio in the second quarter worth about $34,000. Tower Research Capital LLC TRC lifted its holdings in AnaptysBio by 248.8% in the third quarter. Tower Research Capital LLC TRC now owns 3,596 shares of the biotechnology company’s stock worth $65,000 after buying an additional 2,565 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in AnaptysBio by 75.4% in the second quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock worth $101,000 after buying an additional 2,142 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in AnaptysBio by 134.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock worth $106,000 after buying an additional 3,381 shares during the period. Finally, Deutsche Bank AG lifted its holdings in AnaptysBio by 20.5% in the third quarter. Deutsche Bank AG now owns 9,423 shares of the biotechnology company’s stock worth $169,000 after buying an additional 1,604 shares during the period.

Insider Transactions at AnaptysBio

In related news, CEO Daniel Faga sold 145,940 shares of the business’s stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the completion of the sale, the chief executive officer now directly owns 752,087 shares in the company, valued at $17,132,541.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Dennis Mulroy sold 3,065 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $23.63, for a total value of $72,425.95. Following the transaction, the chief financial officer now owns 964 shares of the company’s stock, valued at $22,779.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Faga sold 145,940 shares of AnaptysBio stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $22.78, for a total value of $3,324,513.20. Following the transaction, the chief executive officer now directly owns 752,087 shares in the company, valued at $17,132,541.86. The disclosure for this sale can be found here. Insiders have sold 157,005 shares of company stock worth $3,586,199 in the last quarter. Company insiders own 35.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on ANAB shares. Piper Sandler started coverage on shares of AnaptysBio in a report on Friday, February 16th. They issued an “overweight” rating and a $80.00 price objective for the company. Wedbush upgraded shares of AnaptysBio from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $20.00 to $34.00 in a report on Tuesday, March 12th. Stifel Nicolaus assumed coverage on shares of AnaptysBio in a report on Wednesday, February 21st. They issued a “buy” rating and a $50.00 price objective for the company. BTIG Research assumed coverage on shares of AnaptysBio in a report on Monday, February 26th. They issued a “buy” rating and a $55.00 price objective for the company. Finally, JPMorgan Chase & Co. decreased their price objective on shares of AnaptysBio from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, April 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $46.22.

AnaptysBio Price Performance

NASDAQ ANAB opened at $21.47 on Thursday. AnaptysBio, Inc. has a 1-year low of $13.36 and a 1-year high of $27.50. The stock has a market capitalization of $574.54 million, a price-to-earnings ratio of -3.53 and a beta of -0.30. The business’s fifty day moving average price is $23.38 and its 200-day moving average price is $20.55.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. The company had revenue of $9.01 million for the quarter, compared to the consensus estimate of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. Equities research analysts anticipate that AnaptysBio, Inc. will post -6.25 EPS for the current year.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.